Becton Dickinson and Company

BD to acquire Bard for $24B

Monday, May 1, 2017

BD (Becton, Dickinson and Company), a global medical technology company, and C. R. Bard, a medical technology leader in the fields of vascular, urology, oncology and surgical specialty products, announced a definitive agreement under which BD will acquire Bard for $317 per Bard common share in cash and stock, for a total consideration of $24 billion. The agreement has been unanimously approved by the Boards of Directors of both companies.

[Read More]

Pete Nicholas to retire at Boston Scientific

Monday, February 29, 2016

Pete M. Nicholas, the company’s co-founder and chairman of its board, will retire from the board of Boston Scientific in May. Nicholas served as Boston Scientific’s chief executive officer and co-chairman of the board since its founding in 1979. In 1995, Pete stepped down as CEO and became its chairman. During his almost 40 years of leadership, the company grew to become a global leader in the field of interventional medicine, improving the lives of patients worldwide.

[Read More]

ICON appoints two in Asia Pacific operations

Monday, October 26, 2015

ICON, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has announced two new leadership appointments to its Asia Pacific operations. Mary Pan has been appointed vice president, Asia Pacific, where she will lead ICON’s continued growth and expansion in the region. Hiroshi Ichikawa has been appointed vice president and general manager of ICON’s operations in Japan.

[Read More]

Optimal Strategix Group launches study matching app

Wednesday, September 16, 2015

Optimal Strategix Group (OSG), based in Newtown, Pa., has launched its CAVII app, available for download in the Apple App Store. CAVII is an iOS-based clinical study matching and analytics platform. Ushering in a new era of patient engagement, CAVII’s aim is to revolutionize clinical studies through the use of analytics for superior patient matching. Through CAVII, clinical studies could become more cost-effective, efficient and ultimately more engaging and insightful for patients and clinicians.

[Read More]